How CMR Substance Bans Play Out Across Jurisdictions

You'd think a substance that's carcinogenic, mutagenic, or toxic to reproduction, the category regulators shorthand as CMR, would just be banned everywhere the moment the science lands. It isn't. Different markets classify substances on different timelines, using different review bodies, and a formula that's clean for one region can still be sitting on a restricted list somewhere else.

Why CMR substances get special treatment

Most restricted or prohibited ingredient lists group substances by the type of concern they raise: skin sensitizers, substances with exposure limits, outright prohibitions. CMR substances get pulled into their own category in several regulatory frameworks because the underlying hazard classification, whether something causes cancer, damages genetic material, or harms fertility or development, is usually established first through a broader chemical safety framework, not a cosmetics-specific one. Cosmetics regulation then has to catch up and decide what a CMR classification means for a finished product or an ingredient used in one.

That catching-up step is where the timing differences creep in.

Why the EU, UK, and other markets don't move in lockstep

The European Union regulates cosmetics under Regulation (EC) No 1223/2009, and CMR classifications feed into that framework through the EU's broader chemical classification system. When a substance gets classified as a CMR category 1A, 1B, or 2 substance under that system, it triggers a review and typically restriction or prohibition in cosmetic products, subject to specific exemptions in some cases.

The UK, since leaving the EU, runs its own notification system through the OPSS Submit Cosmetic Product Notification service, and while UK cosmetics regulation started as a mirror of the EU framework, the two don't automatically stay identical going forward. A substance newly classified as CMR in the EU system doesn't necessarily get restricted in the UK on the same day, or vice versa. The two lists can drift.

Markets outside Europe often have their own separate mechanisms entirely. Australia's AICIS treats cosmetic ingredients as industrial chemicals moving through an Inventory and introduction categories, which is a structurally different approach than a per-product notification system reacting to a CMR classification list. Canada works through the Cosmetic Ingredient Hotlist, updated on its own schedule. The United States, under MoCRA, relies more heavily on FDA safety substantiation requirements placed on the responsible person rather than a single centralized prohibited list mirroring CMR classifications elsewhere.

What this means practically

• A formula passing in one market is not evidence it passes in another. Don't treat "compliant in the EU" as a proxy for "compliant everywhere."
• Timing gaps are real. A substance flagged as CMR in one framework can take time to show up as restricted in another market's list, and the reverse is also true, a substance can be restricted somewhere without a CMR classification driving it.
• Exemptions complicate things further. Some frameworks allow continued use of a CMR-classified substance under specific conditions or concentration limits, so "banned" isn't always a clean yes or no.
• Reformulation for one market can create work for another. If you swap out a CMR-flagged ingredient to sell in the EU, check whether the replacement is fine everywhere else you sell.

A simplified comparison

Market	Primary mechanism	How CMR classification connects
EU	Regulation (EC) No 1223/2009, CPNP notification	CMR classification under EU chemical law triggers cosmetic-specific review
UK	OPSS SCPN notification	Own list, originally aligned with EU, can diverge over time
Canada	Cosmetic Ingredient Hotlist	Substance-specific listing, not a direct CMR classification feed
Australia	AICIS Inventory and introduction categories	Industrial chemical framework, not cosmetic-specific CMR review
United States	MoCRA, FDA oversight	Responsible person substantiates safety; fewer centralized prohibitions

The practical takeaway

If you sell into more than one market, or plan to, don't assume your ingredient screening from one jurisdiction transfers cleanly to the next. The safest approach is treating each market's restricted and prohibited list as its own check, run at the time you're preparing that market's filing, since lists get updated on their own schedules and a formula's status can shift under you without a reformulation on your end. This is exactly why Cosmetic Comply screens each market separately with its own confidence-scored review rather than assuming a pass in one place carries over, with Canada live now and the US, EU, and Australia in development.